Heart failure reporting signals associated with concomitant mavacamten and CYP inhibitors in obstructive hypertrophic cardiomyopathy: a real-world pharmacovigilance study with propensity score matching

相伴的 医学 药物警戒 倾向得分匹配 内科学 心力衰竭 优势比 心脏病学 不良事件报告系统 置信区间 回顾性队列研究 不利影响 药理学 CYP2C19型 低风险 危险系数 逻辑回归
作者
Daqiu Chen,Yanqing Wu,Zhanxiong Xie,Qiu Wx,Xiaomai Huang,Shanghua Xu,Shunxiang Luo
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:17: 1846852-1846852 被引量:2
标识
DOI:10.3389/fphar.2026.1846852
摘要

Background Mavacamten, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (HOCM), carries a risk of excessive negative inotropy. Because mavacamten is metabolized primarily by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, concomitant CYP inhibitors may increase mavacamten exposure. We evaluated real-world heart failure-related reporting patterns associated with concomitant CYP inhibitor exposure in mavacamten-treated HOCM reports. Methods We conducted a retrospective pharmacovigilance study using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from the second quarter (Q2) of 2022 to the fourth quarter (Q4) of 2025. Mavacamten-treated HOCM reports were screened for concomitant exposure to ten prespecified CYP2C19 and/or CYP3A4 inhibitors. Heart failure-related signals were defined using seven Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms. Severe outcomes were extracted from FAERS outcome fields; hospitalization was defined as initial or prolonged hospitalization, and death as a reported fatal outcome. Analyses included the reporting odds ratio (ROR), additive signal amplification index (S), time-to-onset modeling, multivariable logistic regression, and 1:4 propensity score matching (PSM). Results Among 3,570 mavacamten-treated HOCM reports, 347 involved concomitant CYP inhibitor exposure. Combination therapy showed an elevated heart failure-related reporting signal (ROR = 25.08; 95% confidence interval [CI], 18.63–33.76) and potential reporting signal amplification (S = 2.71). Agent-specific reporting signals were heterogeneous across prespecified inhibitors. Weibull modeling showed an early-failure pattern (β = 0.88; median onset, 80 days). Compared with mavacamten monotherapy, combination therapy had higher reported proportions of hospitalization (28.5% vs. 13.5%) and death (5.5% vs. 2.3%). Concomitant CYP inhibitor exposure showed higher heart failure-related reporting odds after multivariable adjustment (adjusted odds ratio [aOR], 2.52; 95% CI, 1.10–5.62) and in the PSM sensitivity cohort (aOR, 1.99; P < 0.001). Conclusion Concomitant use of mavacamten with selected CYP inhibitors was associated with increased heart failure-related reporting in FAERS. Careful medication reconciliation and clinical vigilance are warranted, while recognizing that spontaneous reporting data cannot establish causality.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
大模型的应助被玛卡采纳,获得10
1秒前
何文鑫发布了新的文献求助10
1秒前
江子川发布了新的文献求助10
1秒前
夜月残阳发布了新的文献求助10
2秒前
2秒前
2秒前
小浪矢发布了新的文献求助10
2秒前
现代风格完成签到,获得积分10
2秒前
3秒前
ms关闭了ms的文献求助
3秒前
不安寄容完成签到,获得积分10
3秒前
威武语儿完成签到,获得积分20
3秒前
汉堡包的应助被ssn采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
静静发布了新的文献求助10
5秒前
12138完成签到,获得积分10
5秒前
江子川发布了新的文献求助10
5秒前
花花完成签到,获得积分10
5秒前
科研新牛马完成签到,获得积分10
6秒前
null的应助被yy采纳,获得10
6秒前
7秒前
8秒前
8秒前
9秒前
9秒前
9秒前
9秒前
天天快乐的应助被哈哈哈采纳,获得10
9秒前
渺渺完成签到 ,获得积分10
9秒前
万重山发布了新的文献求助10
10秒前
吃个馍馍发布了新的文献求助10
10秒前
江子川发布了新的文献求助10
10秒前
10秒前
洛洛洛完成签到,获得积分10
11秒前
在水一方的应助被畅快蓝血采纳,获得10
11秒前
江子川发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698